You just read:

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

News provided by

Pliant Therapeutics, Inc.

Aug 06, 2018, 08:00 ET